Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average - Should You Sell?

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.28 and traded as high as $4.80. Verastem shares last traded at $4.60, with a volume of 430,557 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have commented on VSTM. Cantor Fitzgerald reissued an "overweight" rating on shares of Verastem in a report on Friday, October 18th. StockNews.com lowered Verastem from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $13.00 price objective on shares of Verastem in a research note on Friday, October 18th. Guggenheim assumed coverage on Verastem in a research report on Monday, September 30th. They set a "buy" rating and a $13.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Verastem in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Verastem has an average rating of "Moderate Buy" and an average target price of $12.50.

Verastem Trading Down 7.4 %

The stock has a market cap of $189.60 million, a PE ratio of -1.34 and a beta of 0.22. The company has a debt-to-equity ratio of 2.77, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a fifty day moving average price of $4.07 and a 200 day moving average price of $3.29.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.11. Equities analysts expect that Verastem, Inc. will post -3.16 EPS for the current year.

Institutional Trading of Verastem

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new stake in shares of Verastem during the third quarter worth $41,000. SG Americas Securities LLC purchased a new position in Verastem in the 3rd quarter worth about $43,000. Apollon Wealth Management LLC lifted its holdings in Verastem by 104.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 20,457 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 10,457 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Verastem in the 2nd quarter valued at about $82,000. Finally, Rhumbline Advisers grew its stake in Verastem by 4,172.0% in the 2nd quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 28,119 shares in the last quarter. 88.37% of the stock is owned by hedge funds and other institutional investors.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.